Navigation Links
Pharma majors gear to supply anti-anthrax drug

The panic that has gripped the U.S with anthrax bacterial infections coming to light has led to an increased demand for the drug used in its treatment - Ciprofloxacin. Already there is news that the German pharma major Bayer is tripling its production of Ciprofloxacin to cater to the burgeoning demand and will supply 200 million tablets in the next three months. In fact, Bayer holds the U.S. patents on the most common forms of Ciprofloxacin and these expire on December 9, 2003. //

Ranbaxy Laboratories produces both the bulk and formulation forms of ciprofloxacin and according to a company spokesman, the U.S. Senator, Mr. Charles Schumer, has approached Ranbaxy's U.S. arm, Ranbaxy Laboratories Inc. regarding supply of Cipro in large numbers - Mr. Schumer had asked Ranbaxy for a supply of 20 million tablets a month of Ciprofloxacin for anthrax treatment starting December. The treatment for anthrax entails one ciprofloxacin twice a day and the U.S. Government wants to purchase enough Ciprofloxacin to cover 12 million patients for 60 days.

Ranbaxy is among the few Indian companies with the U.S. Food and Drug Administration(FDA) approval for the manufacture of Ciprofloxacin. The Mumbai-based Cipla, which is also approved by the U.S. FDA, has also offered to supply large quantities of Ciprofloxacin, the active ingredient of Cipro to a generic producer in the U.S.

Ciprofloxacin is a U.S. FDA wide spectrum antibiotic for the treatment of anthrax and belongs to the fluoroquinolone class of drugs which has a global market of $3.85 billion and is reportedly growing at 16 percent per annum. In India, Ciprofloxacin is the second largest molecule after Amoxycillin.


'"/>




Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharma cos must forge Strategic alliances
4. Medicis Pharmaceutical company enters pediatric market
5. Pharmacies in for a dose of bitter medicine
6. Andhra Pradesh to set up Pharma City
7. Sun Pharma to launch chiral version of omeprazole soon
8. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
9. Pharmacia may take 51.5 percent Abbott stake
10. Pharmaceutical companies are targeting patients
11. FDA approves Watson Pharmaceuticals Oxytrol patch
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... Tiny Transitions ( tinytransitions.com ), ... in-home and online newborn sleep consultations . , “We are seeing now, ... company owner Courtney Zentz, a pediatric sleep professional, post-partum doula and certified lactation ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... book on the fallacy of an obligatory tithe, and the freedom experienced when ... is the creation of published author, Lysa M. Harrison. , Published by Christian ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... you brush more effectively even on the go. Their electric toothbrushes aggressively attack ... gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a ...
(Date:9/22/2017)... ... 22, 2017 , ... Egg freezing and embryo freezing are ... a slight statistical advantage for live births, frozen eggs offer many advantages, depending ... undergoing medical treatment or who are concerned about the decline of their fertility ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for Medical ... p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing ... The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: